Skip to main content

IVIG (Intravenous Immunoglobulin)

An infusion of pooled antibodies used to calm selected autoimmune nerve and eye conditions, often when speed matters but plasma exchange is not ideal.

4 min read

Intravenous immunoglobulin (IVIG) is a pooled antibody treatment made from screened donor plasma. That sounds a little odd the first time you hear it, but the idea is straightforward enough: flood the immune system with normal antibodies so harmful autoimmune activity gets dialed down. In neuro-ophthalmology, IVIG is considered for selected autoimmune nerve and eye conditions, especially when a fast immune reset is needed or plasma exchange is not the right fit.

Key Takeaways

  • Modulates immune activity rather than simply suppressing everything
  • Given as an IV infusion of pooled donor antibodies
  • Used for selected autoimmune conditions, not routine dry eye or routine inflammation
  • Usually tolerated well, though headaches and fatigue are common
  • May be a one-time rescue course or a recurring treatment, depending on the disease

When It's Used

  • Myasthenia gravis, including significant worsening or pre-surgical stabilization
  • MOGAD and some recurrent inflammatory optic nerve disorders
  • Autoimmune optic neuritis, when the pattern fits
  • NMO in selected situations, usually as part of a broader plan
  • Other inflammatory neurologic conditions where the specialist has a clear target

How It Works

IVIG works through several overlapping mechanisms. It can blunt harmful antibodies, calm overactive immune cells, interfere with complement activation, and shift the immune system away from active inflammation. The exact balance depends on the disease being treated.

What to Expect

Before Treatment

  • Blood tests, often including kidney function and blood counts
  • Review of clotting risk, migraine history, kidney disease, and prior infusion reactions
  • Hydration is usually encouraged
  • Premedication with acetaminophen and an antihistamine is common

During Infusion

  • An IV line is placed
  • Infusion starts slowly and is increased stepwise if tolerated
  • Each session may take 4-6 hours
  • A course often runs 2-5 consecutive days, though schedules vary
  • Nurses monitor for headache, chills, rash, blood pressure changes, and other reactions

After Treatment

  • Effects may take days to weeks
  • Fatigue afterward is common; many patients plan reduced activity after infusion days
  • Delayed headache, fever, rash, chest pain, shortness of breath, or neurologic symptoms should be reported promptly

Side Effects

Common

  • Headache
  • Fever, chills
  • Fatigue
  • Muscle aches
  • Nausea

Less Common

  • Allergic reactions
  • Blood clots
  • Kidney problems
  • Aseptic meningitis

Reducing Side Effects

  • Slower infusion rate
  • Premedication
  • Good hydration before and after treatment
  • Switching IVIG brand or dose schedule if reactions keep happening

Frequency

  • Acute treatment may be one course
  • Chronic immune modulation is often every 3-4 weeks
  • The schedule depends on the condition, response, side effects, and what other long-term treatments are being used

Compared to Plasma Exchange

IVIG is usually less invasive than plasma exchange because it uses a regular IV rather than a large catheter. It may take longer to show effect. Plasma exchange physically removes antibodies; IVIG modifies immune activity. Some patients receive both approaches during different phases of care, but this should be directed by the treating specialist.

Frequently Asked Questions

Is IVIG a steroid?

No. IVIG is pooled immunoglobulin, not a corticosteroid. It changes immune behavior through several mechanisms and has a different side-effect profile from prednisone or methylprednisolone.

How soon can IVIG help myasthenia gravis?

For a significant myasthenia worsening, benefit often appears over days to a couple of weeks. It is used as short-term rescue or stabilization, while longer-term immune treatments take effect.

Why do I need kidney and clotting-risk review?

IVIG can rarely contribute to kidney injury or blood clots, especially in higher-risk patients. Hydration, infusion rate, product selection, and monitoring are adjusted around those risks.

Was this article helpful?